Lux Biosciences has begun treating patients in a pivotal clinical trial programme of LX211.
Lux Biosciences has begun treating patients in a pivotal clinical trial programme of LX211, a next-generation calcineurin inhibitor, for the treatment of uveitis.
The trial, LUMINATE (Lux Uveitis Multicentre Investigation of a New Approach to TreatmEnt), consists of three controlled, double masked studies investigating the use of LX211 in different forms of active uveitis and in maintaining control in patients with quiescent disease.
The company expects to enrol more than 500 patients at approximately 45 sites across North America, Europe and India. Efficacy will be measured at six months by assessing the degree of inflammation in the anterior and posterior segments of the eye.